Buchumschlag

Modeling amyloid plaque turnover dynamics improves characterization of drug effects

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Eline van Maanen, Seth Robey, Idriss Bennacef, Stephen Duffull, Michael F. Egan, Matthew E. Kennedy, Julie A. Stone
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Alzheimer's & Dementia: Translational Research & Clinical Interventions
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Plasma amyloid beta biomarkers predict amyloid positivity and longitudinal clinical progression in mild cognitive impairment
von: Takuya Ataka, et al.
Veröffentlicht: (2024)

Vascular cognitive impairment and dementia drug‐development pipeline 2025
von: Ying Xu, et al.
Veröffentlicht: (2026)

Correction to “Masking the transmembrane region of the amyloid β precursor protein as a safe means to lower amyloid β production”
Veröffentlicht: (2024)

Immediate reactions to amyloid PET disclosure in Japanese older adults without dementia
von: Kenichiro Sato, et al.
Veröffentlicht: (2025)

Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer's disease
von: Ronald C. Petersen, et al.
Veröffentlicht: (2025)

Estimating the optimal cutoff for the IGT‐AD Distress subscale adapted for amyloid PET results disclosure
von: Dianxu Ren, et al.
Veröffentlicht: (2025)

Understanding recent advances in non‐amyloid/non‐tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease
von: Linda J. Van Eldik, et al.
Veröffentlicht: (2024)

Alzheimer's disease drug development pipeline: 2026
von: Jeffrey L. Cummings, et al.
Veröffentlicht: (2026)

Alzheimer's disease drug development pipeline: 2025
von: Jeffrey L. Cummings, et al.
Veröffentlicht: (2025)

Data‐driven discovery of associations between prescribed drugs and dementia risk: A systematic review
von: Benjamin R. Underwood, et al.
Veröffentlicht: (2025)

Alzheimer's disease drug development in an evolving therapeutic landscape
von: Stacie Weninger, et al.
Veröffentlicht: (2024)

Evaluation of amyloid change as a surrogate for cognitive decline: demonstration in individual‐level data from the A4 study of solanezumab
von: Sarah F. Ackley, et al.
Veröffentlicht: (2026)

Mapping sex differences in brain and cognition in relation to APOE ε4 and amyloid burden: A longitudinal normative modelling study
von: Sivaniya Subramaniapillai, et al.
Veröffentlicht: (2026)

Anti‐epileptic drug use and subsequent degenerative dementia occurrence
von: Naoki Ikegaya, et al.
Veröffentlicht: (2024)

Clinical efficacy of anti‐amyloid antibodies in apolipoprotein E ε4 homozygotes: A Bayesian reanalysis of lecanemab and donanemab phase 3 results
von: Stefan Teipel, et al.
Veröffentlicht: (2025)

Generating real‐world evidence in early Alzheimer's disease: Considerations for applying the target trial emulation framework to study the safety of anti‐amyloid therapies
von: Xiaojuan Li, et al.
Veröffentlicht: (2025)

Anticholinergic drugs and dementia risk: Using stem cell–based studies to complement pharmacoepidemiology
von: Tiara A. Schwarze‐Taufiq, et al.
Veröffentlicht: (2025)

Genetically proxied IL‐6 signaling and risk of Alzheimer's disease and lobar intracerebral hemorrhage: A drug target Mendelian randomization study
von: Evangelos Pavlos Myserlis, et al.
Veröffentlicht: (2024)

Critical evaluation of real‐world evidence of repurposable medicines in the Alzheimer's disease drug development pipeline using a target trial emulation
von: Reina Tonegawa‐Kuji, et al.
Veröffentlicht: (2025)

Commentary on Greenberg et al., “Prescribing anti‐amyloid immunotherapies to treat Alzheimer's disease: Fully informing patient decisions” [ Alzheimer's Dement . 2023; 9(4):e12426. doi.org/10.1002/trc2.12426]
von: Carl V. Hill, et al.
Veröffentlicht: (2024)

Dementia severity at incident diagnosis in a population representative sample of older Americans
von: Shengjia Xu, et al.
Veröffentlicht: (2024)

Identification of cerebrospinal fluid pharmacodynamic biomarkers and molecular correlates of brain activity in a Phase 2 clinical trial of the Alzheimer's disease drug candidate CT1812
von: Valentina Di Caro, et al.
Veröffentlicht: (2025)

Weight loss and metabolic improvements dominate the microbiome response in the MIND diet intervention: a randomized controlled trial
von: Robin M. Voigt, et al.
Veröffentlicht: (2026)

The plasma p‐tau217/BD‐tau ratio improves biomarker short‐term variability in memory clinic patients
von: Frederikke Kragh Clemmensen, et al.
Veröffentlicht: (2025)

Predicting regional tau accumulation with machine learning‐based tau‐PET and advanced radiomics
von: Saima Rathore, et al.
Veröffentlicht: (2024)

Translation with ongoing adaptation and improvement (ToAI) framework: A community‐informed, structured, iterative approach to culturally adapting cognitive assessment tools
von: Quyen Q. Tiet, et al.
Veröffentlicht: (2025)

The relationship between neurofilament light chain and depressive symptoms according to cognitive status
von: Federico Bellelli, et al.
Veröffentlicht: (2025)

Characterizing clinician communication with patients about lecanemab: A qualitative study of clinicians across seven academic medical centers
von: Anna L. Parks, et al.
Veröffentlicht: (2025)

The power of representation: Statistical analysis of diversity in US Alzheimer's disease genetics data
von: Diane Xue, et al.
Veröffentlicht: (2024)

Measuring time saved in Alzheimer's disease: What is a meaningful slowing of progression?
von: Krista Lanctot, et al.
Veröffentlicht: (2025)

Mechanistic Disease Modeling to Inform Potential Strategies for Early Interventions with BACE inhibition
von: Julie A Stone, et al.
Veröffentlicht: (2024)

Personal value of Alzheimer's disease biomarker testing and result disclosure from the patient and care partner perspective
von: Khushbu J. Patel, et al.
Veröffentlicht: (2024)

Physical activity attenuates the association between allostatic load and early Alzheimer's disease‐related biomarkers in older adults
von: Géraldine Poisnel, et al.
Veröffentlicht: (2026)

Functional connectome metrics reveal distinct prognostic subtypes in two Phase 3 gantenerumab trials
von: Susanna Gobbi, et al.
Veröffentlicht: (2026)

The I‐Learn Cognition and Behavior program for non‐pharmacological treatment of agitation in nursing home residents with neurocognitive disorders: A cluster randomized trial
von: Céline Lourdel, et al.
Veröffentlicht: (2026)

Patterns and predictors of cholinesterase inhibitor use in dementia with Lewy bodies
von: Rachel J. Heo, et al.
Veröffentlicht: (2025)

Mechanistic Model of Alzheimer’s Disease Progression: Linking Amyloid and Tau Pathologies
von: Stephen Duffull, et al.
Veröffentlicht: (2024)

Developing, implementing, and evaluating the first national Memory and Cognition Clinic Guidelines in Australia
von: Inga Mehrani, et al.
Veröffentlicht: (2025)

Discrepancies between self‐ and proxy‐rated quality of life in people living with dementia
von: Maresa Buchholz, et al.
Veröffentlicht: (2024)

Genetic and multi‐omic risk assessment of Alzheimer's disease implicates core associated biological domains
von: Gregory A. Cary, et al.
Veröffentlicht: (2024)